Most Read Articles
Pearl Toh, 03 Jan 2020
Antibiotic resistance of Helicobacter (H.) pylori has more than doubled in Europe in the past two decades, raising alarm on the gravity of the issue of growing bacterial resistance to commonly-used antibiotics, a study presented at UEG Week 2019 has shown.
02 Dec 2019
Utilizing a clinical pharmacist specialist in a hepatitis C virus (HCV) treatment clinic may help improve drug therapy management of HCV-infected patients treated with direct-acting antivirals (DAAs), suggests a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
2 days ago
The use of folic acid in addition to enalapril in the treatment of patients with hypertension yields a modest increase in lifetime stroke-free survival, a study has found.

Faricimab shows therapeutic potential for diabetic macular oedema

19 Aug 2019

Dual inhibition of angiopoietin (Ang)-2 and vascular endothelial growth factor (VEGF)-A with faricimab induces meaningful and superior visual acuity improvements compared with ranibizumab in patients with diabetic macular oedema (DME), according to the results of the phase II BOULEVARD trial.

BOULEVARD included 229 adult patients, among whom 168 were treatment-naïve and 61 were previously treated with anti-VEGF. All patients had centre-involving DME, best-corrected visual acuity (BCVA) of 73 to 24 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, and central subfield thickness (CST) 325 μm.

Treatment-naïve patients were randomly assigned to treatment with intravitreal faricimab at 6.0 mg or 1.5 mg or ranibizumab 0.3 mg. Those with previous exposure to anti-VEGF were randomized to faricimab 6.0 mg or ranibizumab 0.3 mg. Treatment was given monthly for 20 weeks, followed by an observation period up to week 36 to assess durability.

The present trial met its primary endpoint of change in BCVA from baseline at week 24 in treatment-naïve patients. Mean improvements were 13.9 ETDRS letters in the 6.0-mg faricimab group, 11.7 letters in the 1.5-mg faricimab group and 10.3 letters in the ranibizumab group. The visual acuity gain obtained with the 6.0-mg dose was significantly higher than that obtained with ranibizumab (mean difference, 3.6 letters; p=0.03).

In both patient populations, faricimab was associated with dose-dependent reductions in CST, improvements in Diabetic Retinopathy Severity Scale score and longer time to retreatment during the observation period as compared with ranibizumab.

The study drug was well tolerated and showed no new or unexpected safety signals.

Additional long-term benefits of drying the retina, along with the anti-inflammatory properties of faricimab, will be investigated in further studies, according to the investigators.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 03 Jan 2020
Antibiotic resistance of Helicobacter (H.) pylori has more than doubled in Europe in the past two decades, raising alarm on the gravity of the issue of growing bacterial resistance to commonly-used antibiotics, a study presented at UEG Week 2019 has shown.
02 Dec 2019
Utilizing a clinical pharmacist specialist in a hepatitis C virus (HCV) treatment clinic may help improve drug therapy management of HCV-infected patients treated with direct-acting antivirals (DAAs), suggests a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
2 days ago
The use of folic acid in addition to enalapril in the treatment of patients with hypertension yields a modest increase in lifetime stroke-free survival, a study has found.